Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + FOLFIRINOX/NALIRIFOX in 2L Metastatic Pancreatic Cancer
NCT07733050Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Shanghai General Hospital. Primary endpoint: Overall Survival at 24 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07733050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733050.